TMCnet10m
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
Hosted on MSN10m
Has AI discovered the next Ozempic? Researchers in Spain race to patent two plant extracts they think could be the next big thing for weight loss
Morgan Stanley analysts have projected that over the next 10 years, 24 million people - seven percent of the US population - will be taking Ozempic or Wegovy. But users have reported spats of nausea ...
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...